Clinical trials of the anti-coronavirus drug MIR 19 for outpatient treatment have been completed. This was announced by Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA). DEA News”.
According to him, a report is being prepared to expand the indications for use. The drug is expected to appear on the Russian market by the end of August this year.
The drug MIR 19 is effective against all strains of coronavirus studied, including delta, omycron, and other strains. It is administered by inhalation using medical nebulizers. So far, the drug is used only in a hospital setting.
Previously reportedThe coronavirus drug “MIR 19” is planned to be used in hospitals. The FMBA noted that MIR 19 will be used in the first days after a positive test for COVID-19.
Before that, it was known that he was in Russia. registered New drug for COVID-19 – Esperavir.